Free Newsletter
Chinese RU-486 maker sold tainted drugs
Can we trust a Chinese manufacturer that not only sold contaminated cancer drugs but tried to cover up the fact? Apparently, the FDA thinks so. Shanghai Hualian is the sole U.S. supplier of mifepristone (RU-486), the abortion pill. It's also the company under criminal investigation in China for selling tainted leukemia drugs. And the FDA simply won't say whether the company exports any other drugs or pharma ingredients to the U.S.
The mifepristone is made in an entirely different plant run by the company, yes. And--unlike a host of long-uninspected foreign facilities--the FDA inspected this one as recently as May. It passed. China's FDA also has given the plant three look-sees in the last few months and proclaimed it clean. But Chinese regulators also have accused the company of a systematic cover-up of violations at the cancer drug facility.
At least one American drug maker--Pfizer--refuses to buy drug ingredients from Shanghai Pharmaceutical Group because of quality problems. Consumer advocates say Shanghai's problems demand additional scrutiny. "Every one of these plants should be immediately inspected," one told the New York Times.
- read the New York Times article
Related articles:
Overseas drugmaking goes unsupervised. Report
Chinese slam safety violations. Report
Drug-safety hazards many and growing. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: